Avacta has advanced beyond the event horizon with Affimer technology, says CEO Alastair Smith

11 December 2016

Be it in constantly improving the fundamentals of its Affimer technology, engaging with pharma partners on drug discovery programs or developing its own therapeutics pipeline focusing on immuno-oncology and bleeding disorders, UK biotech Avacta (AIM:AVCT) is moving fast to maximize the potential of these non-antibody binding proteins.

The company has progressed rapidly even since The Pharma Letter last spoke to chief executive Alastair Smith at the beginning of the year, with its response to the Zika outbreak a perfect example of its nimble and dynamic approach.

"I can’t think of any other company that will have a significant sized portfolio of binders to a range of targets that are exciting and interesting in immuno-oncology"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK